Bio
Ken is a serial biotech entrepreneur. He serves as Chairman of 5 biotech companies. The last of which is a venture studio, spinning out new biotechs leveraging a novel drug delivery technology out of Stanford. His prior successful exits include IntraBiotics, Fluxion Biosciences, Halozyme, MPEX Pharmaceuticals and PaxVax.
Ken was a Harvard Advanced Leadership Initiative Fellow (2015), an AIMBE (American Institute for Medical and Biological Engineers) 2016 and a White House Presidential Executive Fellow (2016-2017).
Long ago, Ken was biotech venture capitalist with 20+ years of Ser A investing experience in 48 companies with more than 36 successful IPOs or M&A exits at Institutional Venture Partners (IVP), Latterell Venture Partners (LVP) and his own fund (K2).
